Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06696014 · ClinicalTrials.gov registry record
Mirikizumab Real World Protocol
A clinical trial of Ulcerative Colitis, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- 100
- Enrollment target
- 9
- Study locations
NCT06696014: Recruiting study of Ulcerative Colitis, sponsored by University of North Carolina, Chapel Hill.
NCT06696014 is a study of Ulcerative Colitis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 100 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06696014, a study of Ulcerative Colitis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.
Primary Outcome
The SCCAI is a 6-item that describes the symptoms and disease activity of a patient with UC at the time of assessment. A score of 0-4 is considered a clinical range of remission (but with more refined definitions of clinical remission with SCCAI ≤2 and very mild symptoms with a score \>2 ≤4), 5-7 mild activity, 8-16 moderate activity and \> 16 severe activity. A response will be defined as a decrease of the SCCAI score \< 5 points in patients with a baseline SCCAI ≥5.
Conditions Studied
Study Locations (9)
Colorado
- South Denver Gastroenterology - Denver
Florida
- AdventHealth - Orlando
Iowa
- University of Iowa Health Care - Iowa City
Kentucky
- University of Louisville, Clinical Trials Unit - Louisville
New York
- University Of Rochester Medical Center - Rochester
North Carolina
- University of North Carolina - Chapel Hill
South Carolina
- Medical University of South Carolina (MUSC) - Charleston
Texas
- Southern Star Research Institute, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2030-01 |
What NCT06696014 shows while recruiting
NCT06696014 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.
NCT06696014 lists 9 locations in 9 states (Colorado, Florida, Iowa).
Frequently Asked Questions
What is clinical trial NCT06696014 about?
NCT06696014 is a clinical study titled "Mirikizumab Real World Protocol". The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of th...
What is the current status of trial NCT06696014?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-05-08. Estimated completion is 2030-01.
What conditions does trial NCT06696014 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
Who is sponsoring clinical trial NCT06696014?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06696014 being conducted?
This trial has 9 study locations across Colorado, Florida, Iowa, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06696014's enrollment target sits among peer trials
100 67th of 122 higher than 56 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI